Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aripiprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 20/20 | 0.98 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.98 |
| ▸ | DRD3 | P35462 | 5/20 | 0.98 |
| ▸ | DRD4 | P21917 | 4/20 | 0.98 |
| ▸ | HTR2B | P41595 | 3/20 | 0.98 |
| ▸ | DRD1 | P21728 | 2/20 | 0.98 |
| ▸ | DRD5 | P21918 | 2/20 | 0.98 |
| ▸ | HTR2C | P28335 | 2/20 | 0.98 |
| ▸ | HTR7 | P34969 | 2/20 | 0.98 |
| ▸ | HTR6 | P50406 | 2/20 | 0.98 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | MLNR | O43193 | 1/20 | 0.98 |
| ▸ | HTR3B | O95264 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | ESR1 | P03372 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aripiprazole SCHEMBL7097505 | 1.00 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL5606070 | 1.00 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL30958766 | 1.00 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL30958765 | 1.00 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL31174198 | 1.00 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29356997 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29438823 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29475637 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29475638 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL982189 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 680 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115131-A1 | METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-04-30 | — | — | US | claimed |
| CN-121574093-A | Aripiprazole-2, 3-dihydroxybenzoic acid-hydrate crystal form and preparation method thereof | 鲁南制药集团股份有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-20250302826-A1 | METHODS FOR PRODUCING ARIPIPRAZOLE SUSPENSION AND FREEZE-DRIED FORMULATION | OTSUKA PHARMA CO LTD (JP) | 2025-10-02 | — | — | US | claimed |
| EP-3329908-B1 | ORALLY DISPERSIBLE TABLET FORM OF ARIPIPRAZOLE MONOHYDRATE FORMULATIONS | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2025-01-29 | — | — | EP | claimed |
| CN-118858610-A | Gel method-method for determining bacterial endotoxin content of aripiprazole monohydrate | 江苏暨明医药科技有限公司 | 2024-10-29 | — | — | CN | claimed |
| US-20240261280-A1 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD | OTSUKA PHARMA CO LTD (JP) | 2024-08-08 | — | — | US | claimed |
| US-12016927-B2 | Injectable preparation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-25 | — | — | US | claimed |
| US-20240139177-A1 | METHODS FOR PRODUCING ARIPIPRAZOLE SUSPENSION AND FREEZE-DRIED FORMULATION | OTSUKA PHARMA CO LTD (JP) | 2024-05-02 | — | — | US | claimed |
| CN-115554253-B | Aripiprazole freeze-dried preparation for injection capable of stably releasing medicine and preparation method thereof | 浙江圣兆药物科技股份有限公司 | 2024-03-29 | — | — | CN | claimed |
| US-20230390399-A1 | INJECTABLE PREPARATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-12-07 | — | — | US | claimed |
| US-20050277650-A1 | Process for preparing aripirazole hydrate | DR. REDDY'S LABORATORIES LIMITED (IN) | 2005-12-15 | — | — | US | claimed |
| US-20050272742-A1 | Process for making aripiprazole particles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-12-08 | — | — | US | claimed |
| US-20050152981-A1 | Process for making sterile aripiprazole of desired mean particle size | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | claimed |
| US-20050148597-A1 | Controlled release sterile injectable aripiprazole formulation and method | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-07 | — | — | US | claimed |
| WO-2005041937-A2 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | claimed |
| WO-2005041970-A1 | PROCESS FOR MAKING STERILE ARIPIPRAZOLE OF DESIRED MEAN PARTICLE SIZE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-12 | — | — | WO | claimed |
| US-20040058935-A1 | Crystals; storage stability; psychological disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | claimed |
| CN-1463191-A | Low hygroscopic aripiprazole drug substance and process for the preparation thereof | OTSSUKA PHARMA CO LTD (JP) | 2003-12-24 | — | — | CN | claimed |
| EP-1330249-A1 | LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-30 | — | — | EP | claimed |
| WO-2003026659-A1 | LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-04-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016927-B2 | Injectable preparation | TNF, IL1B, F12 | DRD2 782/4885HTR1A 1589/4885HTR2A 2173/4885 |
| US-20050277650-A1 | Process for preparing aripirazole hydrate | AGPS, ABCG2, ATP5PO | DRD2 2961/4885HTR1A 200/4885HTR2A 535/4885 |
| US-20050148597-A1 | Controlled release sterile injectable aripiprazole formulation and method | CYP4F11, YIPF5, CYP4F8 | DRD2 1640/4885HTR1A 565/4885HTR2A 832/4885 |
| US-20230390399-A1 | INJECTABLE PREPARATION | TNF, IL1B, F12 | DRD2 782/4885HTR1A 1589/4885HTR2A 2173/4885 |
| US-20250302826-A1 | METHODS FOR PRODUCING ARIPIPRAZOLE SUSPENSION AND FREEZE-DRIED FORMULATION | EIF4G2, EIF4G1, AP2S1 | DRD2 1064/4885HTR1A 1661/4885HTR2A 1394/4885 |
| US-20240139177-A1 | METHODS FOR PRODUCING ARIPIPRAZOLE SUSPENSION AND FREEZE-DRIED FORMULATION | EIF4G2, EIF4G1, AP2S1 | DRD2 1212/4885HTR1A 1548/4885HTR2A 1301/4885 |
| US-20050152981-A1 | Process for making sterile aripiprazole of desired mean particle size | CYP3A43, CYP2A6, CYP11A1 | DRD2 3163/4885HTR1A 559/4885HTR2A 591/4885 |
| US-20050272742-A1 | Process for making aripiprazole particles | CYP3A4, CYP2F1, CYP2A6 | DRD2 489/4885HTR1A 321/4885HTR2A 210/4885 |
| US-20240261280-A1 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD | CYP4F11, YIPF5, CYP4F8 | DRD2 1640/4885HTR1A 565/4885HTR2A 832/4885 |
| US-20260115131-A1 | METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATION | HTR2A, ADRA2A, HTR1A | DRD2 14/4885HTR1A 3/4885HTR2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.